Aegerion Pharmaceuticals confirmed that it is under a federal magnifying glass again. The company disclosed in a financial statement that it was subpoenaed by the Department of Justice (DOJ) over its cholesterol drug, lomitapide.
The subpoena requested that the Cambridge, Mass.-based company provide documents about sales and marketing of lomitapide. Lomitapide (Juxtapid) has been approved as an adjunct to a low-fat diet and other treatments that lower lipids in patients with homozygous familial hypercholesterolemia.
In November 2013, Aegerion CEO Marc Beer received a warning letter from the FBI, which accused him of misbranding Juxtapid during appearances on a CNBC show “Fast Money.”
The company said it is cooperating with the DOJ in its investigation.